Krystal Biotech, Inc. (KRYS) has a MoatMap StockRank of 93/100 based on Quality (84/100), Value (19/100), and Momentum (80/100) factor scores. The current signal is STRONG BUY. Krystal Biotech is a high-quality gene therapy leader with a massive moat. Crucially, they own their own commercial-scale GMP manufacturing facilities (ANCORIS and ASTEC). In an era where CDMO capacity is highly constrained and expensive, Krystal's vertical integration acts as a massive structural cost advantage and bypasses the CDMO bottleneck entirely, making them a premium second-order beneficiary.
Krystal Biotech, Inc. is a biotechnology company developing and commercializing gene therapies for patients with rare diseases, with an initial focus on serious dermatological conditions. Its proprietary "STAR-D" gene therapy platform provides a competitive moat by enabling repeat administration of gene therapies, distinguishing its approach in the rapidly evolving genetic medicine landscape. Krystal is a niche player with a lead product, Vyjuvek, now commercialized for Dystrophic Epidermolysis Bullosa (DEB).
| Price | $309.75 |
| Market Cap | $9.1B |
| P/E (TTM) | 41.09 |
| P/E (Forward) | 30.53 |
| Price/Book | 7.10 |
| Return on Equity | 19.9% |
| Return on Invested Capital | 13.1% |
| Debt/Equity | 0.71 |
| Gross Margin | 94.2% |
| Operating Margin | 46.1% |
| Revenue Growth | 31.9% |
| Free Cash Flow | $137M |
Krystal Biotech, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).